EUCTR2019-002636-82-IT进行中（未招募）1 期
An open label, non-randomised trial to evaluate the safety and efficacy of a single infusion of OTL-200 in patients with Late Juvenile (LJ) Metachromatic Leukodystrophy (MLD)
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Documented biochemical and molecular diagnosis of MLD, based on ARSA activity below the normal range and identification of two disease causing ARSA alleles. Novel mutations will be analysed within silico prediction tool and excluded from being known common polymorphisms. In the case of a novel mutation(s), a 24-hour urine collection must show elevated sulfatide levels.
- •2. O/R or R/R genotype or a genotype recognized as associated with the LJ variant of MLD.
- •3. a) if symptomatic: age at disease onset between =7 and <17 years of age (i.e. before their 17th birthday) OR b) if pre-symptomatic: participant must be <17 years of age at treatment (i.e before their 17th birthday) AND must have a sibling with a diagnosis of late-juvenile MLD variant based on age at disease onset (=7 and <17 years of age i.e before sibling's 17th birthday), with biochemical and molecular diagnosis.
- •4. Normal cognitive function as defined by an IQ= 85 on age appropriate cognitive scales.
- •5.a) If the participant is <7 years age (i.e before their 7th birthday): normal motor milestones achievement, normal gross motor function according to chronological age and normal neurological examination (if applicable based on the age of the subject, GMFC-MLD =0) OR b) If the participant is =7 years, normal gross motor function or mild gross motor function impairment, defined by a GMFC-MLD 0or 1 (i.e patient is able to walk independently).
- •6. If applicable, participant willing and capable of compliance with contraceptive requirements as detailed further in Protocol Section 7.1 Contraceptive use by men or women should be consistent with local regulations regarding he methods of contraception for those participating in clinical studies.
- •7. Participant (or if applicable, parent/legal guardian) providing signed informed consent as described in Section 17 which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 6
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Documented HIV infection (positive HIV RNA and/or anti-p24 antibodies).
- •2.Malignant neoplasia (except localised skin cancer) or a documented history of hereditary cancer syndrome. Participants with a prior successfully treated malignancy and a sufficient follow-up to exclude recurrence (based on oncologist opinion) can be included after discussion and approval by the OTL-MM.
- •3.Myelodysplasia, cytogenetic alterations characteristic of myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML) or other serious haematological disorders.
- •4.Patients currently enrolled in other interventional trials.
- •5.Has previously undergone allogeneic HSCT and has evidence of residual cells of donor origin.
- •6.Previous gene therapy.
- •7.Has symptomatic herpes zoster, not responsive to specific treatment
- •8.Evidence of active tuberculosis (TB)
- •9.Acute or chronic stable Hepatitis B (HBV)
- •10.Presence of positive Hepatitis C RNA test result at screening
- •11.End-organ dysfunction, severe active infection not responsive to treatment, or other severe disease or clinical condition which, in the judgement of the investigator, would make the participant inappropriate for entry into this study
研究者
相似试验
进行中（未招募）
1 期
A clinical trial to evaluate the effect of OTL-200, a gene therapy treatment in patients with Late Juvenile (LJ) Metachromatic Leukodystrophy (MLD)Metachromatic Leukodystrophy (MLD) is an autosomal recessive disorder caused by mutationsMedDRA version: 20.0Level: PTClassification code: 10067609Term: Metachromatic leukodystrophy Class: 100000004850CTIS2024-511971-13-00Orchard Therapeutics (Europe) Limited6
进行中（未招募）
1 期
An open-label, non-randomized study to evaluate the efficacy and safety of BAY 94-9172 (ZK 6013443) positron emission tomography (PET) imaging for detection/exclusion of cerebral ß-amyloid when compared to postmortem histopathology - Safety and efficacy of positron emission tomography imaging with BAY 94-9172 (ZK 6013443)Detection/Exclusion of cerebral ß-amyloid.To determine the sensitivity and specificity of the visual assessment of regional tracer uptake in the BAY 94-9172 PET images compared to histological verification of the presence or absence of cerebral ß-amyloid in the respective postmortem specimens as the standard of truth.MedDRA version: 9.1Level: LLTClassification code 10001896Term: Alzheimer's diseaseEUCTR2009-012569-79-FRBayer HealthCare AG218
进行中（未招募）
1 期
Safety and efficacy of PET imaging with BAY 94-9172 (ZK 6013443)EUCTR2009-012569-79-DEBayer AG250
尚未招募
不适用
An Open Label, Non-randomised study to evaluate the safety, efficacy, tolerability and compliance of the Tongue Tamer Mandibular Advancement Splint in patients with Obstructive Sleep ApnoeaObstructive Sleep ApnoeaRespiratory - Sleep apnoeaACTRN12615000037505Prof. Peter Cistulli15
进行中（未招募）
不适用
An open label non-controlled trial to evaluate the effect of dronedarone (Multaq® 400 mg BID) on the quality of life in patiënts with a history of, or current non-permanent atrial fibrillation (AF) - HEMERAEUCTR2010-018976-25-BEsanofi-aventis Belgium